Fulltext

Patients with IgA nephropathy exhibit high systemic PDGF-DD levels

Boor, Peter ; Eitner, Frank ; Cohen, Clemens D. ; Lindenmeyer, Maja T. ; Mertens, Peter R. ; Ostendorf, Tammo ; Floege, Jürgen

In: Nephrology Dialysis Transplantation, 2009, vol. 24, no. 9, p. 2755-2762

Ajouter à la liste personnelle
    Titre
    • Patients with IgA nephropathy exhibit high systemic PDGF-DD levels
    Auteur
    • Boor, Peter
    • Eitner, Frank. Division of Nephrology and Immunology, RWTH University of Aachen, Germany and Department of Nephrology
    • Cohen, Clemens D.. Institute of Physiology and Nephrology Clinic, University of Zürich, Zürich, Switzerland
    • Lindenmeyer, Maja T.. Institute of Physiology and Nephrology Clinic, University of Zürich, Zürich, Switzerland
    • Mertens, Peter R.
    • Ostendorf, Tammo. Division of Nephrology and Immunology, RWTH University of Aachen, Germany and Department of Nephrology
    • Floege, Jürgen. Division of Nephrology and Immunology, RWTH University of Aachen, Germany and Department of Nephrology
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Nephrology Dialysis Transplantation, 2009, vol. 24, no. 9, p. 2755-2762. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:294804
    Summary
    Background. Platelet-derived growth factor (PDGF) is a central mediator of mesangioproliferative glomerulonephritis (GN). In experimental mesangioproliferative GN, PDGF-DD serum levels, unlike PDGF-BB, increased up to 1000-fold. Methods. We assessed disease activity in 72 patients with GN, established a novel PDGF-D ELISA and then determined their PDGF-DD levels. In parallel, we studied renal PDGF-DD mRNA expression by RT-PCR. Results. PDGF-DD serum levels in patients with IgA nephropathy (IgAN) were significantly higher (1.67 ± 0.45 ng/ml) and in patients with lupus nephritis significantly lower (0.66 ± 0.86 ng/ml) compared to healthy controls (1.17 ± 0.46 ng/ml), while patients with focal segmental glomerulosclerosis, membranous GN and ANCA-positive vasculitis did not differ from controls. The subgroup of IgAN patients with elevated PDGF-DD levels (27% of samples) did not differ in their clinical features from those with normal PDGF-DD levels. In IgAN patients with repetitive PDGF-DD determinations, most exhibited only minor fluctuations of serum levels over time. Intrarenal PDGF-DD mRNA expression did not differ between controls and patients, suggesting an extrarenal source of the elevated PDGF-DD in IgAN. Conclusions. Serum PDGF-DD levels were specifically elevated in patients with IgAN, in particular in those with early disease, i.e. preserved renal function. Our data support the rationale for anti-PDGF-DD therapy in mesangioproliferative GN